DaVita股价表现 - DaVita Inc. (DVA)的股价本周出现大幅上涨，尤其是在周二，这是由于Novo Nordisk (NVO)宣布其肥胖治疗方案显著降低慢性肾病患者的死亡风险达到24%[1] - DaVita的股价本周迄今上涨了5.7%，而Fresenius Medical Care的股价本周上涨了6.7%[3] - DaVita的股价目前接近其2021年中期创下的历史最高价136.48美元，反映了上涨趋势的延续[3] Novo Nordisk研究数据 - Novo Nordisk的研究数据显示，在患有2型糖尿病和慢性肾病的患者中，药物semaglutide每周剂量可使患者死于肾脏或心血管问题的风险降低24%，而接受安慰剂的患者则没有这种效果[5] - Novo Nordisk计划向美国食品和药物管理局申请批准semaglutide在患有2型糖尿病和慢性肾病的患者中使用，该药物在减肥方面被市场为Wegovy，在糖尿病治疗方面被市场为Ozempic[6] 投资者关注点 - 投资者担心GLP-1类药物（如Ozempic）的好处与心脏事件有关，而不是对肾病进展的改变。这对透析服务提供商未来似乎是有利的，因为它消除了竞争因素的风险[7] 股票推荐 - DaVita目前拥有Zacks Rank 1（强烈买入）[8] - 另一个值得考虑的股票是Cardinal Health (CAH)，目前也拥有Zacks Rank 1，该公司的长期增长率估计为15.9%[9]

Shares of DaVita Inc. (DVA) scaled a new 52-week high of $136.29 on Mar 5, before closing the session slightly lower at $134.65. Over the past year, this Zacks Rank #1 (Strong Buy) stock has gained 70.8% compared with the industry’s 22.4% rise and the S&P 500’s 25.4% growth. Over the past five years, the company registered earnings growth of 15.5% compared with the industry’s 5.8% rise. The company’s long-term expected growth rate of 12.1% compares with the industry’s growth projection of 11.2%. DaVita’s ea ...

DaVita国际业务扩张 - DaVita Inc.最近宣布扩大其国际业务，涉及巴西和哥伦比亚，并进入智利和厄瓜多尔[1] - 交易在智利已经生效，而在厄瓜多尔、哥伦比亚和巴西的交易仍需通过各自国家的反垄断和监管审批流程[2] DaVita在拉丁美洲的业务提升 - 最新交易预计将显著提升DaVita在拉丁美洲的业务，并巩固其在这一领域的立足点[3] - 根据管理层的说法，完成交易并与DaVita在巴西和哥伦比亚的现有拉丁美洲业务结合后，公司可能能够为超过270家诊所的超过6万名患者提供临床护理，从而使DaVita成为拉丁美洲最大的透析服务提供商[4]

DaVita HealthCare股价表现 - DaVita HealthCare (DVA)股价在过去一个月上涨了20.1%，创下了新的52周高点[1] - DaVita HealthCare自今年年初以来涨幅达28.5%，远超过医疗行业和门诊医疗与家庭保健行业的涨幅[2] - 公司目前的估值指标显示，虽然股价处于52周高位，但与同行业平均值相比，目前的估值并不处于最优水平[5] DaVita HealthCare财务表现 - 公司在过去四个季度中均未错过盈利预期，最近一次财报显示，EPS为$1.87，超过了预期$1.53，同时收入也超出了预期4.82%[3] - 预计本财年，DaVita HealthCare的每股收益将为$8.97，营收为$124.7亿，同比分别增长5.9%和2.74%；下一财年预计每股收益为$9.77，营收为$129.1亿，同比增长8.93%和3.47%[4] DaVita HealthCare投资建议 - 根据Zacks Style Scores显示，公司的价值评分为A，成长和动量评分分别为C和C，综合VGM评分为B[6] - 公司目前的Zacks Rank为1（强烈买入），得益于盈利预期的增长[8] - 根据Zacks建议，投资者应选择Zacks Rank为1（强烈买入）或2（买入）以及风格评分为A或B的股票，DaVita HealthCare符合这些要求，因此股价可能还有上涨空间[9] Addus HomeCare Corporation表现 - Addus HomeCare Corporation上一季度的盈利表现强劲，预计本财年每股收益为$4.84，营收为$11.4亿[11] - Addus HomeCare Corporation股价在过去一个月上涨了11.8%，目前的前瞻市盈率为20.18倍，现金流市盈率为19.36倍[12]

Expansion would make DaVita the largest dialysis services provider in Latin America DENVER, March 5, 2024 /PRNewswire/ -- DaVita Inc (NYSE: DVA), a leading provider of kidney care services, today announced that it has agreed to terms on the expansion of its international operations in Brazil and Colombia, and its entry into Chile and Ecuador. The deal, which is consistent with DaVita's disciplined investment strategy, involves four separate acquisitions from Fresenius Medical Care for a total purchase price ...

In a market dealing with external shocks, value investing is fast gaining popularity. The success of value investors like Warren Buffett underscores this. Buffett and his business partner, Charlie Munger, managed to register more than 20% CAGR for Berkshire Hathaway from 1965 through 2022. This compares favorably with a 10% rise of the S&P 500 during the same period. Several other stocks, which have surged significantly in the recent past, have shown the overwhelming success of this pure-play investment str ...

DENVER, Feb. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at TD Cowen's Health Care Conference 2024 on Monday, March 4, 2024, at 11:10 a.m. EST. To view the live webcast, visit the TD Cowen page and create a free registration. About DaVita Inc. DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Whi ...

Zacks Style Scores - Zacks Premium提供多种方式帮助投资者充分利用股市并增强投资信心[1] - Zacks Style Scores是一套独特的指导原则，根据三种流行的投资类型对股票进行评级，帮助投资者选择未来30天内市场表现最佳的证券[3] - Style Scores分为四个类别：价值评分、成长评分、动量评分和VGM评分，每个股票根据其价值、成长和动量特征被分配A、B、C、D或F等级[5]

股市表现和趋势 - 股市自年初以来表现强劲，但存在一些令人担忧的迹象[1] - 纳斯达克100指数突破上升趋势通道下限[2] - 通道突破可能预示更多波动性[3] - 利率预期逆转可能引发市场进一步下跌[7] 经济和就业数据 - 通胀数据高于预期，可能导致降息风险[5] - 就业数据显示劳动力市场非常强劲[5] - 经济仍在扩张，央行可能不急于降息[6] 市场趋势和投资建议 - 季节性趋势显示市场可能面临较大卖压[9] - 领先股票出现回调迹象，转向低风险、非周期性股票[11] - 医疗股具有防御性特点，值得关注[16] - HCA Healthcare和DaVita是两只值得关注的医疗股[17] - General Motors是另一只具有潜力的防御性股票[21] 市场风险和机会 - 市场存在一些令人担忧的因素，包括利率、技术突破和地缘政治紧张局势[24] - 尽管存在悲观因素，但仍有牛市机会[27]